Home » Healthcare » Pharmaceuticals » Peptide Therapeutics Market

Peptide Therapeutics Market By Type of Peptide (Glucagon-Like Peptide-1 (GLP-1) Agonists, Insulin, Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues, Glucagon and Glucagon Analogs, Enkephalins and Endorphins); By Application (Metabolic Disorders, Oncology, Cardiovascular Disorders, Central Nervous System (CNS) Disorders, Gastrointestinal Disorders, Bone and Joint Disorders); By Route of Administration (Subcutaneous Injection, Intravenous Infusion, Oral Administration, Nasal Administration, Transdermal Delivery, Calcitonin, Oxytocin and Vasopressin Analogs); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Peptide Therapeutics Market Size 2023	USD 49781.9 Million
Peptide Therapeutics Market, CAGR	7.80%
Peptide Therapeutics Market Size 2032	USD 97867.91 Million

Market Insights

Between 2024 and 2032, the market for peptide therapeutics is projected to rise at a compound annual growth rate (CAGR) of 7.80%, from an estimated USD 49781.9 million in 2023 to USD 97867.91 million in 2032.
The largest category is glucagon-like peptide-1 (GLP-1) agonists. Insulin, on the other hand, is expected to grow at a strong CAGR.
The metabolic disorders category will expand at a rapid rate of growth.
The CAGR for subcutaneous injection is expected to be the highest during the projection period.
North America governed the market for peptide therapeutics.
Regarding the market share of peptide therapeutics, Europe is expected to come second.
In the peptide therapeutics market, Asia Pacific is anticipated to grow fastest.
The main drivers of the global market’s expansion are increased investments in R&D, the growth of the biotech sector, and the exploration of peptide therapies for a variety of indications that go beyond conventional fields like cancer, such as infectious illnesses, autoimmune disorders, and metabolic disorders.
Growing point-of-care diagnostics, integration of artificial intelligence, and the creation of peptide drug conjugates, peptides combined with small molecules or cytotoxic agents, are creating new opportunities for targeted treatment in cancer and other disorders, leading to the development of the peptide therapeutics industry.

Executive Summary

Market Definition

The pharmaceutical industry’s focus on creating and promoting therapeutic peptides, short sequences of amino acids, is known as the Peptide Therapeutics Market. These peptides can target particular biological processes, which may lead to the development of therapies for a range of disorders. The market includes peptide-based therapy research, development, production, and distribution.

Market Overview

The peptide therapeutics sector is predicted to continue its upward trend between 2024 and 2032, growing at a compound annual growth rate (CAGR) of 7.80%. From its projected USD 49781.9 million in 2023 to USD 97867.91 million in 2032, the market will continue to grow.

Peptide therapies are predicted to become more widely used in the coming years due to the rising incidence of cancer and metabolic diseases, including diabetes, obesity, and osteoporosis. The growing number of children with these illnesses and the fact that they are typically found in low-income areas make it necessary to develop reasonably priced and potent medications.

The market is expected to rise as a result of rising rates of various malignancies and the rising need for suitable treatment alternatives. For example, the International Agency for Research on Cancer (IARC) estimates that in 2023 there will be about 20.7 million new cases of cancer. Early cancer treatment with peptide therapies can enhance disease control and lower mortality. Throughout the projected period, rising demand for effective and quick-acting medications is anticipated to drive market expansion. Cancer is one of the top causes of mortality worldwide, expected to account for 10 million deaths in 2020, or one in every six people. It is estimated that alcohol misuse, smoking, obesity, high body mass index, and high cholesterol account for one-third of cancer-related fatalities.

As companies concentrate on creating innovative medications, the market is expected to rise at a profitable CAGR throughout the forecast period. In order to provide therapies for the illnesses they are targeting and grow their market share, players are heavily investing in research and development (R&D). In peptide therapies, cancer and infectious illnesses come in second and third, respectively, after metabolic disorders. Peptide therapy laws are changing, moving toward more strict standards for approval in the areas of safety, effectiveness, and quality. The FDA and EMA are among the regulatory agencies currently reviewing new guidelines aimed at streamlining the approval process for peptide medicines.

Segmentation by Type of Peptide

The glucagon-like peptide-1 (GLP-1) agonists category is the market leader in terms of the type of peptide. GLP-1 agonists function similarly to endogenous GLP-1, a hormone the intestines manufacture in reaction to food consumption. They reduce blood glucose levels by stimulating glucose-dependent insulin production from pancreatic beta cells. Patients with T2DM benefit from improved glycemic control due to this mechanism.
The insulin category will exhibit a sizable CAGR during the projected period. Insulin therapy is widely used to assist pregnant women with gestational diabetes mellitus (GDM) in achieving their glycemic goals when dietary and lifestyle modifications are insufficient. Strict glycemic control is crucial during pregnancy to mitigate the possibility of negative outcomes for both the mother and the fetus, and insulin therapy is often initiated to achieve this goal.
Other types of peptides, including growth hormone (GH) and growth hormone-releasing hormone (GHRH) analogs, glucagon and glucagon analogs, and enkephalins and endorphins, also support the need for peptide therapeutics.

Segmentation by Application

Metabolic disorders are considered the best application category. A 2023 National Centre for Biotechnology Information (NCBI) article estimates that 20–30% of adult people worldwide are thought to have metabolic syndrome (MetS), which has serious negative effects on health, society, and the economy. Additionally, peptides may replicate or modify naturally occurring substances related to respiration, including leptin insulin and GLP-1 receptor agonists. By regulating these biological processes, peptide treatments can aid in the restoration of normal metabolic function and advance the segment.
The oncology category will likely register a significant CAGR during forecasting. Peptides are thought to be a promising cytotoxic agent with the potential to treat cancer successfully. The oncology industry’s increased need for practical yet potent treatments has propelled the cancer segment’s expansion in recent times. Another reason propelling the development of a sector in the global peptide therapeutics market is the growing number of discoveries about parenteral peptide medicines for cancer therapy.
Other applications, such as cardiovascular disorders, central nervous system (CNS) disorders, gastrointestinal disorders, and bone and joint disorders, also contribute to the demand for peptide therapeutics.

Segmentation by Route of Administration

The category of subcutaneous injection is anticipated to expand at a quicker rate during the forecast period. Because the needle is inserted into the fatty tissue layer immediately beneath the skin (subcutaneous tissue) rather than deep into the muscle, subcutaneous injections are usually less painful than intramuscular injections. This lessens the pain and discomfort that come with injections, which improves patient acceptability and treatment compliance.
Other routes of administration, including intravenous infusion, oral administration, nasal administration, transdermal delivery, calcitonin, and oxytocin and vasopressin analogs, influence the need for peptide therapeutics.

Segmentation by Region

North America leads the peptide therapeutics industry. This is due to the increasing regional demand for peptide medicinal products used to treat cancer.
Europe is estimated to rank second in peptide therapeutics market size.
The peptide therapeutics industry is predicted to flourish rapidly in Asia Pacific.
Regions such as Latin America, Africa, and the Middle East cover the remaining need for peptide therapeutics.

Moreover, the market for peptide therapies is growing, mostly due to the increased number of senior individuals. Furthermore, throughout the forecast period, technological developments in the pharmaceutical sector are anticipated to propel market expansion. Numerous peptide conjugates have anti-inflammatory, weight-loss, and inflammatory-reducing properties. The need for peptide medications has increased due to a boom in the nutrition and health sectors.

Based on projections, North America is anticipated to control the peptide therapeutics market due to the introduction of effective products and the construction of state-of-the-art industrial facilities throughout the area. Furthermore, market expansion is anticipated due to the rising incidence of illnesses, including cancer, heart disease, respiratory conditions, infectious diseases, metabolic disorders, and others. For example, the Cancer Atlas states that cancer accounts for around 1.9 million new cases in the area each year and is the main cause of death in Canada and the second largest cause of death in the United States after heart disease. One of the leading causes of mortality in the United States is cardiovascular disease, which includes heart disease, stroke, heart failure, and hypertension.

The market for peptide therapeutics in Asia Pacific is predicted to grow considerably throughout the projection period due to a number of factors, including unexplored markets, cheap raw material prices, an increasing number of outsourcing service providers, the biotech industry’s growth, and increased R&D expenditures. Furthermore, because new medicine patents are expiring and raw material costs are falling, the generic industry is anticipated to expand at a rapid pace of compound annual growth. The combination of all these factors would offer the area plenty of growth prospects.

Key Highlights of the Report

The global peptide therapeutics market is segmented by type of peptide, application, route of administration, and region. The glucagon-like peptide-1 (GLP-1) agonists category is the market spearhead in terms of the type of peptide, and metabolic disorders are the top-application category. The subcutaneous injection category is anticipated to increase at the highest CAGR throughout the projection period. The peptide therapeutics market is expanding mostly in North America.

Improvements in peptide synthesis techniques are anticipated to support industry expansion. The goal of suppliers and manufacturers is to create novel peptide synthesis techniques. Reduction in waste production, automation, and enhancement of the purification process continue to propel the market expansion further. To expedite the development of peptide therapies, Creative Peptides, for example, launched cutting-edge peptide drug discovery services in March 2022. In addition, scientists at universities and research centers are developing cutting-edge methods to create peptide medicines. Hokkaido University researchers created a novel strategy in February 2023 for designing and producing peptide antibiotics on a big scale to manage antibiotic resistance.

North America is expected to account for the largest peptide therapeutics market globally. In North America, the nation has a high prevalence of diabetes, cardiovascular disorders, and cancer, which increases demand for novel biopharmaceuticals. For instance, according to the Canadian Cancer Statistics 2021, which was published in November 2021, there were an anticipated 229,200 cancer diagnoses in Canada. As a result, the nation’s high cancer case rate is propelling the researched market and creating opportunities for novel peptide therapies. It is also anticipated that the market will develop at the fastest rate in the Asia Pacific region. The region’s market demand is anticipated to be driven by the rise in diabetes and cancer incidence in nations like China, India, and Japan as a result of aging populations, changes in lifestyle, and environmental factors.

Which Key Factors Are Driving The Global Peptide Therapeutics Market?

The rise in chronic illnesses, a growing elderly population, and the high efficacy and selectivity of peptide drugs are contributing to the growth of the peptide therapeutics market.

What Are The Main Challenges Confronting The Global Peptide Therapeutics Market?

Limited oral bioavailability and peptide synthesis involve labor-intensive and sophisticated manufacturing procedures, which raise production costs and may hamper the product’s affordability and marketability. These factors impede the expansion of the market.

What Market Opportunities Exist For Peptide Therapeutics Globally?

Increasing personalized medicine approaches, growing therapeutic applications, and improvements in drug delivery technologies are some of the factors creating opportunities for the peptide therapeutics market.

Market Drivers

Multiple factors propel the peptide therapeutics industry across the globe. The primary factors propelling the global peptide therapeutics market are as follows:

Rising Prevalence of Chronic Illnesses

The market value of peptide therapies is increasing because the number of persistent illnesses is increasing, which is also driving demand for innovative treatments. Six out of ten persons in the US have at least one chronic illness, and four out of ten have two or more, as per the information provided by the Centers for Disease Control and Protection. In the United States, the incidence of diabetes has climbed from 8.0% in 2010 to 10.2% in 2020. The second leading cause of death is cancer globally, accounting for 9.9 million deaths in 2020.

Comparing peptide medicines to conventional small molecule and biological medications reveals a host of benefits. A 2021 study discovered that the peptide therapy semaglutide was useful in lowering blood sugar levels and enhancing cardiovascular outcomes in individuals with type 2 diabetes. Additionally, the use of peptides in cancer treatment offers encouraging prospects for the market for peptide therapies to expand in the future.

Market Restraints

There are several obstacles that the global peptide therapeutics market must overcome to continue growing. Among them are the following:

End of Exclusive Market Position and Biosimilars’ Availability

The costly and time-consuming process of finding and creating novel medicines delays their eventual commercialization. As a result, during the projection, a sizable portion of the medications are in danger of losing their market exclusivity. The accessibility of general or recombinant peptide therapeutic pharmaceuticals, together with the anticipated release of more drugs over the projection period, may provide a challenge to the global market’s growth and valuation. Initiatives by regulating organizations and regulatory agencies to expand the availability of generic and biosimilar medications due to their reduced pricing may influence the global market for peptide treatments.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Opportunities

The global peptide therapeutics sector has a plethora of promising opportunities. Among these are the following:

Advancements in Peptide Synthesis Technologies

Peptide production has become more scalable and efficient because of ongoing developments in peptide synthesis techniques, including liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS). This makes it possible to produce peptide medications on a greater scale and satisfy the market’s increasing demand. As a result of advancements in peptide synthesis technology, manufacturing procedures are now less expensive. As a result, peptide therapies become more widely available and cheap, increasing their market share and uptake. With the use of sophisticated purification processes and strict quality control measures made possible by modern peptide synthesis techniques, high-purity peptides with few contaminants are produced. Ensuring the safety and efficacy of peptide medications is imperative in order to enhance customer confidence and maintain regulatory compliance.

Competitive Landscape

Key Players

In the highly competitive global peptide therapeutics market, there are a number of significant rivals. A few of the top market players are shown below, together with their respective market shares:

Eli Lilly and Company (U.S.)
Pfizer Inc. (U.S.)
Amgen Inc. (U.S.)
Takeda Pharmaceutical Company Limited (Japan)
AstraZeneca PLC (UK)
Novo Nordisk A/S (Denmark)
GlaxoSmithKline PLC (UK)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Novartis AG (Switzerland)
Ironwood Pharmaceuticals Inc. (U.S.)
Others

To stay competitive, these businesses give priority to product innovation, expanding their distribution networks, and completing mergers and acquisitions.

The biggest vendors in the global peptide therapeutics market consistently strive to keep one step ahead of the competition by creating cutting-edge ideas and goods.

In October 2023, Biosynth acquired Pepceuticals Limited, a British synthetic peptide producer, to bolster its peptide business.

In March 2023, Macrocyclic Constrained Peptide Therapeutics development and drug discovery are being conducted in collaboration with Ono Pharmaceuticals and PeptiDream.

In November 2022, Enterome created one of the first-in-class immunomodulatory drugs utilizing its bacterial-mimicking drug creation technology. Enterome released the safety, immunogenicity, and efficacy results for treating individuals with glioblastoma who are either in the beginning stages of the illness or have recurred of its Phase 1/2 clinical study of EO2401 in conjunction with an immune checkpoint inhibitor (ROSALIE trial).

How are Companies Performing in the Peptide Therapeutics Market?

Several remarkable factors have contributed to the notable performance of companies in the peptide therapeutics market. To remain competitive in the market, numerous companies are making investments in the creation of new pharmaceuticals. These companies are working constantly on research and development in order to deliver novel medications that are helpful for patients suffering from a range of illnesses. More clinical trials for these medications have been conducted in recent years, which is anticipated to accelerate market expansion. For instance, a new agreement to continue their partnership in the field of peptide therapies was signed in June 2023 by Merck & Co. Inc. and the Italian contract research organization (IRBM). Access to Merck’s vast resources and knowledge of the planning and conduct of clinical trials is provided under this arrangement.

The major companies are participating in research projects in addition to strategic alliances like acquisitions and collaborations to broaden their product ranges internationally. Prominent peptide therapeutics companies are focusing on growing their market share through joint ventures, distribution agreements, and white space research. Furthermore, well-known companies are working with local companies to strengthen their local presence and increase their manufacturing capacity. For example, In February 2022, Plexium, Inc. and Amgen declared a multiyear license agreement and research collaboration aimed at developing novel targeted protein degradation treatments for previously untreatable pharmacological targets. Using Amgen’s expertise in producing multispecific compounds, the multiyear collaboration may facilitate the development of novel molecular glue therapies.

Summary of Key Findings

The global market is expanding because of favorable regulatory regulations and an increase in the number of regulatory approvals for peptide pharmaceuticals.
The market is segmented by type of peptide, application, route of administration, and region.
The glucagon-like peptide-1 (GLP-1) agonists category is estimated to develop at a significant CAGR over the forecast period.
Metabolic disorders are the foremost application category.
The subcutaneous injection category is expected to grow fastest in terms of CAGR during the forecast period.
North America is leading market development; the market is highly competitive with key players including Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca PLC (UK), Novo Nordisk A/S (Denmark), GlaxoSmithKline PLC (UK), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Ironwood Pharmaceuticals Inc. (U.S.), and Others.

Future Outlook

The peptide therapeutics industry is expected to increase significantly in North America, and its outlook is positive worldwide.
The rising demand for biological drugs is driving the expansion of the global market for peptide therapeutics.
Peptide synthesis involves labor-intensive and complicated manufacturing procedures that can increase manufacturing costs, cause scaling issues, and create production constraints.
To remain competitive, major corporations must develop new products, expand their customer base, and keep their prices low.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

How the Credence Research Peptide Therapeutics Market Report Can Help CXOs

The Credence Research Peptide Therapeutics Market Report provides CXOs with an extensive market overview and comprises the following:

Market size and growth forecast: The study offers comprehensive market estimations for peptide therapeutics globally, broken down by type of peptide, application, route of administration, and region. In addition, projections for the market through 2032 based on significant drivers and trends are included.
Market segmentation: The peptide therapeutics market is divided into segments by type of peptide, application, route of administration, and region in the research report. CXOs are given a detailed grasp of the market and the potential inside each sector due to this segmentation.
Competitive landscape: The study report provides a thorough analysis of the leading businesses in the peptide therapeutics sector, together with details on their revenue streams, product lines, and business strategies. This information can help CXOs assess and identify their competitors.
Key trends and drivers: The study report analyzes and highlights the key developments and elements driving the market for peptide therapeutics. CXOs can utilize this information to make well-informed choices regarding their plans and investments.

The Credence Research Peptide Therapeutics Market Report provides CXOs with insights that they may utilize to:

Identify growth opportunities: This analysis is likely to help CXOs find fresh growth prospects in the peptide therapeutics sector. For example, the research recognizes the increasing requirement for peptide therapeutics from the healthcare sector as a crucial opportunity.
Make informed investment decisions: The study aids CXOs in making informed decisions about peptide therapeutics. For example, it delivers information on the key variables to consider while picking solutions and evaluating suppliers.
Develop competitive strategies: CXOs can utilize the research report to establish competitive strategies for their peptide therapeutics firms. The study paper explores the primary tactics employed by peptide therapeutics providers to set themselves apart from their rivals.
Track market developments: By tracking market advancements, this research report could assist CXOs in remaining ahead of the curve. For example, it provides information about the latest advancements and patterns in the peptide therapeutics industry.

The Credence Research Peptide Therapeutics Market Report is helpful for CXOs who want to learn more about the market and identify potential opportunities.

Segmentation

By Type of Peptide
- Glucagon-Like Peptide-1 (GLP-1) Agonists
- Insulin
- Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues
- Glucagon and Glucagon Analogs
- Enkephalins and Endorphins
By Application
- Metabolic Disorders
- Oncology
- Cardiovascular Disorders
- Central Nervous System (CNS) Disorders
- Gastrointestinal Disorders
- Bone and Joint Disorders
By Route of Administration
- Subcutaneous Injection
- Intravenous Infusion
- Oral Administration
- Nasal Administration
- Transdermal Delivery
- Calcitonin
- Oxytocin and Vasopressin Analogs
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - The Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets in the peptide therapeutics market have high revenue growth opportunities. The key adjacent markets for the peptide therapeutics market

Adjacent Markets
Biologics Market	Cancer Therapeutics Market	Infectious Diseases Market
Drug Delivery Technologies	Metabolic Disorders Market	Biomaterials Market
Personalized Medicine Market	Immunotherapy Market	Genetic Engineering Market

Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Peptide Therapeutics Market
2.1.1. Global Peptide Therapeutics Market, By Type of Peptide
2.1.2. Global Peptide Therapeutics Market, By Application
2.1.3. Global Peptide Therapeutics Market, By Route of Administration
2.1.4. Global Peptide Therapeutics Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Peptide Therapeutics Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Peptide Therapeutics Market Drivers
3.2.2. Peptide Therapeutics Market Restraints
3.2.3. Peptide Therapeutics Market Opportunities
3.2.4. Major Peptide Therapeutics Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type of Peptide
3.5.2. Application
3.5.3. Route of Administration
3.5.4. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Peptide Therapeutics Market: Company Market Share, Value 2023
4.1.2. Global Peptide Therapeutics Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Peptide Therapeutics Market: Top 3 Company Market Share, Value 2023
4.2. Global Peptide Therapeutics Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Peptide Therapeutics Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Peptide Therapeutics Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Peptide Therapeutics Market, By Type of Peptide
8.1. Global Peptide Therapeutics Market Overview, by Type of Peptide
8.1.1. Global Peptide Therapeutics Market Revenue Share, By Type of Peptide, 2023 Vs 2032 (in %)
8.2. Glucagon-Like Peptide-1 (GLP-1) Agonists
8.2.1. Global Peptide Therapeutics Market, By Glucagon-Like Peptide-1 (GLP-1) Agonists, By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for Glucagon-Like Peptide-1 (GLP-1) Agonists
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Insulin
8.3.1. Global Peptide Therapeutics Market, By Insulin, By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for Insulin
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues
8.4.1. Global Peptide Therapeutics Market, By Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues, By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Glucagon and Glucagon Analogs
8.5.1. Global Peptide Therapeutics Market, By Glucagon and Glucagon Analogs, By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for Glucagon and Glucagon Analogs
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Enkephalins and Endorphins
8.6.1. Global Peptide Therapeutics Market, By Enkephalins and Endorphins, By Region, 2019-2032 (US$ Mn)
8.6.2. Market Dynamics for Enkephalins and Endorphins
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
9. Global Peptide Therapeutics Market, By Application
9.1. Global Peptide Therapeutics Market Overview, by Application
9.1.1. Global Peptide Therapeutics Market Revenue Share, By Application, 2023 Vs 2032 (in %)
9.2. Metabolic Disorders
9.2.1. Global Peptide Therapeutics Market, By Metabolic Disorders, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Metabolic Disorders
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Oncology
9.3.1. Global Peptide Therapeutics Market, By Oncology, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Oncology
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Cardiovascular Disorders
9.4.1. Global Peptide Therapeutics Market, By Cardiovascular Disorders, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Cardiovascular Disorders
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Central Nervous System (CNS) Disorders
9.5.1. Global Peptide Therapeutics Market, By Central Nervous System (CNS) Disorders, By Region, 2019-2032 (US$ Mn)
9.5.2. Market Dynamics for Central Nervous System (CNS) Disorders
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
9.6. Gastrointestinal Disorders
9.6.1. Global Peptide Therapeutics Market, By Gastrointestinal Disorders, By Region, 2019-2032 (US$ Mn)
9.6.2. Market Dynamics for Gastrointestinal Disorders
9.6.2.1. Drivers
9.6.2.2. Restraints
9.6.2.3. Opportunities
9.6.2.4. Trends
9.7. Bone and Joint Disorders
9.7.1. Global Peptide Therapeutics Market, By Bone and Joint Disorders, By Region, 2019-2032 (US$ Mn)
9.7.2. Market Dynamics for Bone and Joint Disorders
9.7.2.1. Drivers
9.7.2.2. Restraints
9.7.2.3. Opportunities
9.7.2.4. Trends
10. Global Peptide Therapeutics Market, By Route of Administration
10.1. Global Peptide Therapeutics Market Overview, by Route of Administration
10.1.1. Global Peptide Therapeutics Market Revenue Share, By Route of Administration, 2023 Vs 2032 (in %)
10.2. Subcutaneous Injection
10.2.1. Global Peptide Therapeutics Market, By Subcutaneous Injection, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Subcutaneous Injection
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Intravenous Infusion
10.3.1. Global Peptide Therapeutics Market, By Intravenous Infusion, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Intravenous Infusion
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Oral Administration
10.4.1. Global Peptide Therapeutics Market, By Oral Administration, By Region, 2019-2032 (US$ Mn)
10.4.2. Market Dynamics for Oral Administration
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Nasal Administration
10.5.1. Global Peptide Therapeutics Market, By Nasal Administration, By Region, 2019-2032 (US$ Mn)
10.5.2. Market Dynamics for Nasal Administration
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
10.6. Transdermal Delivery
10.6.1. Global Peptide Therapeutics Market, By Transdermal Delivery, By Region, 2019-2032 (US$ Mn)
10.6.2. Market Dynamics for Transdermal Delivery
10.6.2.1. Drivers
10.6.2.2. Restraints
10.6.2.3. Opportunities
10.6.2.4. Trends
10.7. Calcitonin
10.7.1. Global Peptide Therapeutics Market, By Calcitonin, By Region, 2019-2032 (US$ Mn)
10.7.2. Market Dynamics for Calcitonin
10.7.2.1. Drivers
10.7.2.2. Restraints
10.7.2.3. Opportunities
10.7.2.4. Trends
10.8. Oxytocin and Vasopressin Analogs
10.8.1. Global Peptide Therapeutics Market, By Oxytocin and Vasopressin Analogs, By Region, 2019-2032 (US$ Mn)
10.8.2. Market Dynamics for Oxytocin and Vasopressin Analogs
10.8.2.1. Drivers
10.8.2.2. Restraints
10.8.2.3. Opportunities
10.8.2.4. Trends
11. Global Peptide Therapeutics Market, By Region
11.1. Global Peptide Therapeutics Market Overview, by Region
11.1.1. Global Peptide Therapeutics Market, By Region, 2023 Vs 2032 (in%)
11.2. Type of Peptide
11.2.1. Global Peptide Therapeutics Market, By Type of Peptide, 2019-2032 (US$ Mn)
11.3. Application
11.3.1. Global Peptide Therapeutics Market, By Application, 2019-2032 (US$ Mn)
11.4. Route of Administration
11.4.1. Global Peptide Therapeutics Market, By Route of Administration, 2019-2032 (US$ Mn)
12. North America Peptide Therapeutics Market Analysis
12.1. Overview
12.1.1. Market Dynamics for North America
12.1.1.1. Drivers
12.1.1.2. Restraints
12.1.1.3. Opportunities
12.1.1.4. Trends
12.2. North America Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
12.5.1. North America Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
12.5.2. U.S.
12.5.3. Canada
12.5.4. Mexico
13. Europe Peptide Therapeutics Market Analysis
13.1. Overview
13.1.1. Market Dynamics for Europe
13.1.1.1. Drivers
13.1.1.2. Restraints
13.1.1.3. Opportunities
13.1.1.4. Trends
13.2. Europe Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
13.5.1. Europe Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
13.5.2. UK
13.5.3. France
13.5.4. Germany
13.5.5. Italy
13.5.6. Spain
13.5.7. Benelux
13.5.8. Russia
13.5.9. Rest of Europe
14. Asia Pacific Peptide Therapeutics Market Analysis
14.1. Overview
14.1.1. Market Dynamics for Asia Pacific
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. Asia Pacific Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
14.5.1. Asia Pacific Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
14.5.2. China
14.5.3. Japan
14.5.4. India
14.5.5. South Korea
14.5.6. South East Asia
14.5.7. Rest of Asia Pacific
15. Latin America Peptide Therapeutics Market Analysis
15.1. Overview
15.1.1. Market Dynamics for Latin America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Latin America Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
15.5.1. Latin America Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
15.5.2. Brazil
15.5.3. Argentina
15.5.4. Rest of Latin America
16. Middle East Peptide Therapeutics Market Analysis
16.1. Overview
16.1.1. Market Dynamics for Middle East
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Middle East Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
16.5.1. Middle East Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
16.5.2. UAE
16.5.3. Saudi Arabia
16.5.4. Rest of Middle East
17. Africa Peptide Therapeutics Market Analysis
17.1. Overview
17.1.1. Market Dynamics for Africa
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Africa Peptide Therapeutics Market, by Type of Peptide, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Africa Peptide Therapeutics Market, by Application, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Africa Peptide Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Africa Peptide Therapeutics Market, by Country, 2019-2032 (US$ Mn)
17.5.1. Africa Peptide Therapeutics Market, by Country, 2023 Vs 2032 (in%)
17.5.2. South Africa
17.5.3. Egypt
17.5.4. Rest of Africa
18. Company Profiles
18.1. Eli Lilly and Company (U.S.)
18.1.1. Company Overview
18.1.2. Products/Services Portfolio
18.1.3. Geographical Presence
18.1.4. SWOT Analysis
18.1.5. Financial Summary
18.1.5.1. Market Revenue and Net Profit (2019-2023)
18.1.5.2. Business Segment Revenue Analysis
18.1.5.3. Geographical Revenue Analysis
18.2. Pfizer Inc. (U.S.)
18.3. Amgen Inc. (U.S.)
18.4. Takeda Pharmaceutical Company Limited (Japan)
18.5. AstraZeneca PLC (UK)
18.6. Novo Nordisk A/S (Denmark)
18.7. GlaxoSmithKline PLC (UK)
18.8. Teva Pharmaceutical Industries Ltd. (Israel)
18.9. Sanofi (France)
18.10. F. Hoffmann-La Roche Ltd. (Switzerland)
18.11. Novartis AG (Switzerland)
18.12. Ironwood Pharmaceuticals Inc. (U.S.)
18.13. Others
19. Research Methodology
19.1. Research Methodology
19.2. Phase I – Secondary Research
19.3. Phase II – Data Modelling
19.3.1. Company Share Analysis Model
19.3.2. Revenue Based Modelling
19.4. Phase III – Primary Research
19.5. Research Limitations
19.5.1. Assumptions

List of Figures
FIG. 1 Global Peptide Therapeutics Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Peptide Therapeutics Market Segmentation
FIG. 4 Global Peptide Therapeutics Market, by Type of Peptide, 2023 (US$ Mn)
FIG. 5 Global Peptide Therapeutics Market, by Application, 2023 (US$ Mn)
FIG. 6 Global Peptide Therapeutics Market, by Route of Administration, 2023 (US$ Mn)
FIG. 7 Global Peptide Therapeutics Market, by Geography, 2023 (US$ Mn)
FIG. 8 Attractive Investment Proposition, by Type of Peptide, 2023
FIG. 9 Attractive Investment Proposition, by Application, 2023
FIG. 10 Attractive Investment Proposition, by Route of Administration, 2023
FIG. 11 Attractive Investment Proposition, by Geography, 2023
FIG. 12 Global Market Share Analysis of Key Peptide Therapeutics Market Manufacturers, 2023
FIG. 13 Global Market Positioning of Key Peptide Therapeutics Market Manufacturers, 2023
FIG. 14 Global Peptide Therapeutics Market Value Contribution, By Type of Peptide, 2023 & 2032 (Value %)
FIG. 15 Global Peptide Therapeutics Market, by Glucagon-Like Peptide-1 (GLP-1) Agonists, Value, 2019-2032 (US$ Mn)
FIG. 16 Global Peptide Therapeutics Market, by Insulin, Value, 2019-2032 (US$ Mn)
FIG. 17 Global Peptide Therapeutics Market, by Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues, Value, 2019-2032 (US$ Mn)
FIG. 18 Global Peptide Therapeutics Market, by Glucagon and Glucagon Analogs, Value, 2019-2032 (US$ Mn)
FIG. 19 Global Peptide Therapeutics Market, by Enkephalins and Endorphins, Value, 2019-2032 (US$ Mn)
FIG. 20 Global Peptide Therapeutics Market Value Contribution, By Application, 2023 & 2032 (Value %)
FIG. 21 Global Peptide Therapeutics Market, by Metabolic Disorders, Value, 2019-2032 (US$ Mn)
FIG. 22 Global Peptide Therapeutics Market, by Oncology, Value, 2019-2032 (US$ Mn)
FIG. 23 Global Peptide Therapeutics Market, by Cardiovascular Disorders, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Peptide Therapeutics Market, by Central Nervous System (CNS) Disorders, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Peptide Therapeutics Market, by Gastrointestinal Disorders, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Peptide Therapeutics Market, by Bone and Joint Disorders, Value, 2019-2032 (US$ Mn)
FIG. 27 4Global Peptide Therapeutics Market Value Contribution, By Route of Administration, 2023 & 2032 (Value %)
FIG. 28 Global Peptide Therapeutics Market, by Subcutaneous Injection, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Peptide Therapeutics Market, by Intravenous Infusion, Value, 2019-2032 (US$ Mn)
FIG. 30 Global Peptide Therapeutics Market, by Oral Administration, Value, 2019-2032 (US$ Mn)
FIG. 31 Global Peptide Therapeutics Market, by Nasal Administration, Value, 2019-2032 (US$ Mn)
FIG. 32 Global Peptide Therapeutics Market, by Transdermal Delivery, Value, 2019-2032 (US$ Mn)
FIG. 33 Global Peptide Therapeutics Market, by Calcitonin, Value, 2019-2032 (US$ Mn)
FIG. 34 Global Peptide Therapeutics Market, by Oxytocin and Vasopressin Analogs, Value, 2019-2032 (US$ Mn)
FIG. 35 North America Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 36 U.S. Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 37 Canada Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 38 Mexico Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 39 Europe Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 40 Germany Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 41 France Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 42 U.K. Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 43 Italy Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 44 Spain Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 45 Benelux Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 46 Russia Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 47 Rest of Europe Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 48 Asia Pacific Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 49 China Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 50 Japan Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 51 India Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 52 South Korea Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 53 South-East Asia Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 54 Rest of Asia Pacific Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 55 Latin America Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 56 Brazil Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 57 Argentina Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 58 Rest of Latin America Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 59 Middle East Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 60 UAE Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 61 Saudi Arabia Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 62 Rest of Middle East Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 63 Africa Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 64 South Africa Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 65 Egypt Peptide Therapeutics Market, 2019-2032 (US$ Mn)
FIG. 66 Rest of Africa Peptide Therapeutics Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Peptide Therapeutics Market
TABLE 2 Global Peptide Therapeutics Market: Market Drivers Impact Analysis
TABLE 3 Global Peptide Therapeutics Market: Market Restraints Impact Analysis
TABLE 4 Global Peptide Therapeutics Market, by Competitive Benchmarking, 2023
TABLE 5 Global Peptide Therapeutics Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Peptide Therapeutics Market, by Key Strategies Analysis, 2023
TABLE 7 Global Peptide Therapeutics Market, by Glucagon-Like Peptide-1 (GLP-1) Agonists, By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Peptide Therapeutics Market, by Glucagon-Like Peptide-1 (GLP-1) Agonists, By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Peptide Therapeutics Market, by Insulin, By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Peptide Therapeutics Market, by Insulin, By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Peptide Therapeutics Market, by Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues, By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Peptide Therapeutics Market, by Growth Hormone (GH) and Growth Hormone-Releasing Hormone (GHRH) Analogues, By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Peptide Therapeutics Market, by Glucagon and Glucagon Analogs, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Peptide Therapeutics Market, by Glucagon and Glucagon Analogs, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Peptide Therapeutics Market, by Enkephalins and Endorphins, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Peptide Therapeutics Market, by Enkephalins and Endorphins, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Peptide Therapeutics Market, by Metabolic Disorders, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Peptide Therapeutics Market, by Metabolic Disorders, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Peptide Therapeutics Market, by Oncology, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Peptide Therapeutics Market, by Oncology, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Peptide Therapeutics Market, by Cardiovascular Disorders, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Peptide Therapeutics Market, by Cardiovascular Disorders, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Peptide Therapeutics Market, by Central Nervous System (CNS) Disorders, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Peptide Therapeutics Market, by Central Nervous System (CNS) Disorders, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Peptide Therapeutics Market, by Gastrointestinal Disorders, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Peptide Therapeutics Market, by Gastrointestinal Disorders, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Peptide Therapeutics Market, by Bone and Joint Disorders, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Peptide Therapeutics Market, by Bone and Joint Disorders, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Peptide Therapeutics Market, by Subcutaneous Injection, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Peptide Therapeutics Market, by Subcutaneous Injection, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Peptide Therapeutics Market, by Intravenous Infusion, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Peptide Therapeutics Market, by Intravenous Infusion, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Peptide Therapeutics Market, by Oral Administration, By Region, 2019-2023 (US$ Mn)
TABLE 34 Global Peptide Therapeutics Market, by Oral Administration, By Region, 2024-2032 (US$ Mn)
TABLE 35 Global Peptide Therapeutics Market, by Nasal Administration, By Region, 2019-2023 (US$ Mn)
TABLE 36 Global Peptide Therapeutics Market, by Nasal Administration, By Region, 2024-2032 (US$ Mn)
TABLE 37 Global Peptide Therapeutics Market, by Transdermal Delivery, By Region, 2019-2023 (US$ Mn)
TABLE 38 Global Peptide Therapeutics Market, by Transdermal Delivery, By Region, 2024-2032 (US$ Mn)
TABLE 39 Global Peptide Therapeutics Market, by Calcitonin, By Region, 2019-2023 (US$ Mn)
TABLE 40 Global Peptide Therapeutics Market, by Calcitonin, By Region, 2024-2032 (US$ Mn)
TABLE 41 Global Peptide Therapeutics Market, by Oxytocin and Vasopressin Analogs, By Region, 2019-2023 (US$ Mn)
TABLE 42 Global Peptide Therapeutics Market, by Oxytocin and Vasopressin Analogs, By Region, 2024-2032 (US$ Mn)
TABLE 43 Global Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 44 Global Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 45 Global Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 46 Global Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 47 Global Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 48 Global Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 49 Global Peptide Therapeutics Market, by Region, 2019-2023 (US$ Mn)
TABLE 50 Global Peptide Therapeutics Market, by Region, 2024-2032 (US$ Mn)
TABLE 51 North America Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 52 North America Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 53 North America Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 54 North America Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 55 North America Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 56 North America Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 57 North America Peptide Therapeutics Market, by Country, 2019-2023 (US$ Mn)
TABLE 58 North America Peptide Therapeutics Market, by Country, 2024-2032 (US$ Mn)
TABLE 59 United States Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 60 United States Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 61 United States Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 62 United States Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 63 United States Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 64 United States Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 65 Canada Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 66 Canada Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 67 Canada Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 68 Canada Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 69 Canada Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 70 Canada Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 71 Mexico Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 72 Mexico Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 73 Mexico Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 74 Mexico Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 75 Mexico Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 76 Mexico Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 77 Europe Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 78 Europe Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 79 Europe Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 80 Europe Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 81 Europe Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 82 Europe Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 83 Europe Peptide Therapeutics Market, by Country, 2019-2023 (US$ Mn)
TABLE 84 Europe Peptide Therapeutics Market, by Country, 2024-2032 (US$ Mn)
TABLE 85 Germany Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 86 Germany Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 87 Germany Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 88 Germany Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 89 Germany Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 90 Germany Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 91 France Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 92 France Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 93 France Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 94 France Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 95 France Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 96 France Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 97 United Kingdom Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 98 United Kingdom Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 99 United Kingdom Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 100 United Kingdom Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 101 United Kingdom Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 102 United Kingdom Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 103 Italy Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 104 Italy Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 105 Italy Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 106 Italy Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 107 Italy Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 108 Italy Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 109 Spain Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 110 Spain Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 111 Spain Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 112 Spain Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 113 Spain Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 114 Spain Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 115 Benelux Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 116 Benelux Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 117 Benelux Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 118 Benelux Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 119 Benelux Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 120 Benelux Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 121 Russia Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 122 Russia Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 123 Russia Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 124 Russia Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 125 Russia Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 126 Russia Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 127 Rest of Europe Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 128 Rest of Europe Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 129 Rest of Europe Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 130 Rest of Europe Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 131 Rest of Europe Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 132 Rest of Europe Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 133 Asia Pacific Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 134 Asia Pacific Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 135 Asia Pacific Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 136 Asia Pacific Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 137 Asia Pacific Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 138 Asia Pacific Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 139 China Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 140 China Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 141 China Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 142 China Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 143 China Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 144 China Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 145 Japan Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 146 Japan Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 147 Japan Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 148 Japan Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 149 Japan Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 150 Japan Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 151 India Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 152 India Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 153 India Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 154 India Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 155 India Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 156 India Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 157 South Korea Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 158 South Korea Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 159 South Korea Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 160 South Korea Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 161 South Korea Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 162 South Korea Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 163 South-East Asia Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 164 South-East Asia Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 165 South-East Asia Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 166 South-East Asia Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 167 South-East Asia Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 168 South-East Asia Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 169 Rest of Asia Pacific Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 170 Rest of Asia Pacific Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 171 Rest of Asia Pacific Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 172 Rest of Asia Pacific Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 173 Rest of Asia Pacific Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 174 Rest of Asia Pacific Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 175 Latin America Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 176 Latin America Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 177 Latin America Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 178 Latin America Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 179 Latin America Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 180 Latin America Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 181 Brazil Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 182 Brazil Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 183 Brazil Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 184 Brazil Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 185 Brazil Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 186 Brazil Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 187 Argentina Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 188 Argentina Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 189 Argentina Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 190 Argentina Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 191 Argentina Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 192 Argentina Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 193 Rest of Latin America Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 194 Rest of Latin America Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 195 Rest of Latin America Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 196 Rest of Latin America Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 197 Rest of Latin America Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 198 Rest of Latin America Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 199 Middle East Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 200 Middle East Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 201 Middle East Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 202 Middle East Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 203 Middle East Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 204 Middle East Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 205 UAE Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 206 UAE Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 207 UAE Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 208 UAE Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 209 UAE Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 210 UAE Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 211 Saudi Arabia Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 212 Saudi Arabia Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 213 Saudi Arabia Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 214 Saudi Arabia Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 215 Saudi Arabia Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 216 Saudi Arabia Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 217 Rest of Middle East Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 218 Rest of Middle East Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 219 Rest of Middle East Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 220 Rest of Middle East Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 221 Rest of Middle East Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 222 Rest of Middle East Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 223 Africa Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 224 Africa Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 225 Africa Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 226 Africa Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 227 Africa Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 228 Africa Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 229 South Africa Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 230 South Africa Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 231 South Africa Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 232 South Africa Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 233 South Africa Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 234 South Africa Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 235 Egypt Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 236 Egypt Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 237 Egypt Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 238 Egypt Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 239 Egypt Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 240 Egypt Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)
TABLE 241 Rest of Africa Peptide Therapeutics Market, by Type of Peptide, 2019-2023 (US$ Mn)
TABLE 242 Rest of Africa Peptide Therapeutics Market, by Type of Peptide, 2024-2032 (US$ Mn)
TABLE 243 Rest of Africa Peptide Therapeutics Market, by Application, 2019-2023 (US$ Mn)
TABLE 244 Rest of Africa Peptide Therapeutics Market, by Application, 2024-2032 (US$ Mn)
TABLE 245 Rest of Africa Peptide Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)
TABLE 246 Rest of Africa Peptide Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

Frequently Asked Questions:

How much does the global market currently hold for peptide therapeutics?

In 2023, the peptide therapeutics market was estimated to be worth USD 49781.9 million.

What is the peptide therapeutics market’s projected growth rate between 2024 and 2032?

The peptide therapeutics market is anticipated to increase at a CAGR of 7.80% from 2024 to 2032, reaching USD 97867.91 million in 2032.

What is the most significant market segment in terms of type of peptide?

Glucagon-like peptide-1 (GLP-1) agonists are the most popular type of peptide category.

Regarding the application, which market category is in the lead?

The noteworthy application segment is metabolic disorders.

Which route of administration is anticipated to grow at the fastest rate throughout the projected period?

The subcutaneous injection is anticipated to have the greatest estimated CAGR over the projected timeframe.

In which region is the market for peptide therapeutics expanding?

North America ruled the peptide therapeutics market.

Who are the main players in the peptide therapeutics industry globally?

The top players include Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca PLC (UK), Novo Nordisk A/S (Denmark), GlaxoSmithKline PLC (UK), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Ironwood Pharmaceuticals Inc. (U.S.), and others.

Which market factors are the primary drivers of the peptide therapeutics industry?

The market for peptide therapeutics is growing due to several factors, including rising healthcare expenditures and technological developments in formulation and delivery systems. The market is also growing due to the expanding pipeline of peptide-based biopharmaceuticals, which includes both innovative medications and biosimilars.

What main market challenges prevent the growth of the peptide therapeutics sector?

The primary barriers to the growth of the peptide therapeutics market are immunogenicity concerns, regulatory hurdles, and limited targeted delivery systems.

What are the main market opportunities for the peptide therapeutics sector?

The market for peptide therapeutics may grow as a result of expanding biodegradable peptide materials, targeting drug-resistant pathogens, and increasing peptide vaccine development.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –